Drivers of Clinical Trial Participation-Demographics, Disparities, and Eligibility Criteria.

JAMA Oncol

Cancer Therapy Evaluation Program, Clinical Investigations and Investigational Drug Branches, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland.

Published: March 2019

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2018.5949DOI Listing

Publication Analysis

Top Keywords

drivers clinical
4
clinical trial
4
trial participation-demographics
4
participation-demographics disparities
4
disparities eligibility
4
eligibility criteria
4
drivers
1
trial
1
participation-demographics
1
disparities
1

Similar Publications

Background: The COVID-19 pandemic was associated with increased psychological distress and psychiatric service usage in Australia. Previous research into the first few months of the pandemic found severe inequality in telehealth psychiatry but no change in inequality for psychiatry service usage overall. However, it is unknown how inequality evolved over the remainder of the pandemic, as extended lockdowns continued in major Australian cities.

View Article and Find Full Text PDF

Background: Caregiver concern is the main driver to paediatric emergency departments visits. Understanding caregiver worries is crucial to guide patients to the most appropriate healthcare setting. Previous research shows mixed findings on the accordance between caregiver assessment and professional triage.

View Article and Find Full Text PDF

Deciphering SPP1-related macrophage signaling in the pathogenesis of intervertebral disc degeneration.

Cell Biol Toxicol

January 2025

Department of Spine Surgery, Honghui Hospital, Xi'an Jiaotong University, No.555 Friendship East Road, South Gate, Beilin District, Xi'an, 710054, Shaanxi, China.

This study delved into the molecular mechanisms underlying mechanical stress-induced intervertebral disc degeneration (msi-IDD) through single-cell and high-throughput transcriptome sequencing in mouse models and patient samples. Results exhibited an upsurge in macrophage presence in msi-IDD intervertebral disc (IVD) tissues, with secreted phosphoprotein 1 (SPP1) identified as a pivotal driver exacerbating degeneration via the protein kinase RNA-like endoplasmic reticulum kinase/ activating transcription factor 4/ interleukin-10 (PERK/ATF4/IL-10) signaling axis. Inhibition of SPP1 demonstrated promising outcomes in mitigating msi-IDD progression in both in vitro and in vivo models.

View Article and Find Full Text PDF

Characterizing biomarkers of ageing in Singaporeans: the ABIOS observational study protocol.

Geroscience

January 2025

Healthy Longevity Translational Research Program, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.

Ageing is the primary driver of age-associated chronic diseases and conditions. Asian populations have traditionally been underrepresented in studies understanding age-related diseases. Thus, the Ageing BIOmarker Study in Singaporeans (ABIOS) aims to characterise biomarkers of ageing in Singaporeans, exploring associations between molecular, physiological, and digital biomarkers of ageing.

View Article and Find Full Text PDF

The important role of the histone acetyltransferases p300/CBP in cancer and the promising anticancer effects of p300/CBP inhibitors.

Cell Biol Toxicol

January 2025

Department of Ultrasound, Shengjing Hospital of China Medical University, 110004, Shenyang, Liaoning, China.

Histone acetyltransferases p300 (E1A-associated protein p300) and CBP (CREB binding protein), collectively known as p300/CBP due to shared sequence and functional synergy, catalyze histone H3K27 acetylation and consequently induce gene transcription. p300/CBP over-expression or over-activity activates the transcription of oncogenes, leading to cancer cell growth, resistance to apoptosis, tumor initiation and development. The discovery of small molecule inhibitors targeting p300/CBP histone acetyltransferase activity, bromodomains, dual inhibitors of p300/CBP and BRD4 bromodomains, as well as proteolysis-targeted-chimaera p300/CBP protein degraders, marks significant progress in cancer therapeutics.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!